Testing a mindfulness meditation mobile app for the treatment of sleep-related symptoms in adults with sleep disturbance: A randomized controlled trial

• Published in: PloS one 2021-01, Vol.16 (1), p.e0244717-e0244717
• Main Authors: Huberty, Jennifer L, Green, Jeni, Puzia, Megan E, Larkey, Linda, Laird, Breanne, Vranceanu, Ana-Maria, Vlisides-Henry, Robert, Irwin, Michael R
• Format: Article
• Language: English
• Subjects: Adult; Adults; Applications programs; Arousal; Arousal - physiology; Biology and Life Sciences; Care and treatment; Clinical trials; Cognitive ability; Computer and Information Sciences; Coronaviruses; COVID-19; Daytime; Disturbance; Engineering and Technology; Fatigue; Feasibility studies; Female; Humans; Insomnia; Intervention; Male; Medicine and Health Sciences; Meditation; Meditation - psychology; Middle Aged; Mindfulness; Mindfulness - methods; Mindfulness meditation; Mobile Applications; Mobile computing; Pandemics; Research and Analysis Methods; Sleep; Sleep and wakefulness; Sleep disorders; Sleep Wake Disorders - psychology; Sleep Wake Disorders - therapy; Sleepiness; Smartphones; Social networks; Social research; Surveys and Questionnaires; Testing; Treatment Outcome
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0244717

The objective of this randomized controlled trial was to test whether a commercially available, mindfulness meditation mobile app, (i.e., Calm app), was effective in reducing fatigue (primary outcome), pre-sleep arousal, and daytime sleepiness (secondary outcomes) in adults with sleep disturbance (Insomnia Severity Index Score >10) as compared to a wait-list control group. Associations between the use of the Calm app (i.e., adherence to the intervention) and changes in sleep quality was also explored in the intervention group only. Adults with sleep disturbance were recruited (N = 640). Eligible and consenting participants (N = 263) were randomly assigned to the intervention (n = 124) or a wait-list control (n = 139) group. Intervention participants were asked to meditate using the Calm app ≥10 minutes/day for eight weeks. Fatigue, daytime sleepiness, and pre-sleep arousal were assessed at baseline, mid- (4-weeks) and post-intervention (8-weeks) in both groups, whereas sleep quality was evaluated only in the intervention group. Findings from intent-to-treat analyses suggest the use of the Calm app for eight weeks significantly decreased daytime fatigue (p = .018) as well as daytime sleepiness (p = .003) and cognitive (p = .005) and somatic (p < .001) pre-sleep arousal as compared to the wait-list control group. Within the intervention group, use of the Calm app was associated with improvements in sleep quality (p < .001). This randomized controlled trial demonstrates that the Calm app can be used to treat fatigue, daytime sleepiness, and pre-sleep arousal in adults with sleep disturbance. Given that the Calm app is affordable and widely accessible, these data have implications for community level dissemination of a mobile app to improve sleep-related symptoms associated with sleep disturbance. Trial registration: ClinicalTrials.gov NCT04045275.